CD274 and small cell lung carcinoma: Recently, IMpower133 trial evaluated the efficacy of PD-L1 inhibitors of atezolizumab in platinum-etoposide chemotherapy for ES-SCLC patients, which showed improvements in OS (12.3m vs. 10.3m) and PFS (5.2m vs. 4.3m) comparing with chemotherapy alone (5).